Dyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co. to “Neutral”

JPMorgan Chase & Co. lowered shares of Dyne Therapeutics (NASDAQ:DYN) from an overweight rating to a neutral rating in a research note released on Thursday morning, Marketbeat Ratings reports. They currently have $35.00 target price on the stock, down from their previous target price of $43.00.

Other analysts also recently issued research reports about the stock. Guggenheim raised their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Morgan Stanley raised their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Piper Sandler restated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Finally, StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $50.60.

Dyne Therapeutics Stock Down 1.6 %

DYN opened at $30.60 on Thursday. The stock has a market cap of $2.67 billion, a PE ratio of -7.83 and a beta of 1.05. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $47.45. The company has a fifty day moving average of $36.63 and a 200-day moving average of $34.63.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. Sell-side analysts anticipate that Dyne Therapeutics will post -2.96 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the transaction, the director now directly owns 234,127 shares of the company’s stock, valued at $8,533,929.15. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at approximately $4,529,594.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is currently owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of Dyne Therapeutics by 25.5% during the fourth quarter. Wellington Management Group LLP now owns 145,474 shares of the company’s stock worth $1,935,000 after acquiring an additional 29,539 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Dyne Therapeutics by 5.9% in the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock worth $437,000 after purchasing an additional 857 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Dyne Therapeutics by 24.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock valued at $812,000 after buying an additional 5,696 shares during the period. Capstone Investment Advisors LLC purchased a new position in shares of Dyne Therapeutics in the first quarter worth about $575,000. Finally, Jennison Associates LLC lifted its stake in shares of Dyne Therapeutics by 495.2% in the 1st quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock valued at $34,282,000 after acquiring an additional 1,004,680 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.